DexCom, Inc. (NASDAQ:DXCM) Q4 2023 Earnings Conference Call February 8, 2024 4:30 PM ET
Company Participants
Sean Christensen - Head of Investor Relations
Kevin Sayer - Chairman, President, and Chief Executive Officer
Jereme Sylvain - Chief Financial Officer
Conference Call Participants
Robbie Marcus - JPMorgan Chase and Company
Danielle Antalffy - UBS
Larry Biegelsen - Wells Fargo Securities
Mathew Blackman - Stifel Financial Corp.
Marie Thibault - BTIG
Jeff Johnson - Robert W. Baird and Company
Matt Taylor - Jefferies
Travis Steed - Bank of America Merrill Lynch
Joanne Wuensch - Citi
Matthew O'Brien - Piper Sandler
Malgaret Andrew - William Blair and Company
Jayson Bedford - Raymond James
Bill Plovanic - Canaccord Genuity
Michael Polark - Wolfe Research
Chris Pasquale - Nephron
Josh Jennings - TD Cowen
Mike Kratky - Leerink Partners
Steve Lichtman - Oppenheimer and Company
Matt Miksic - Barclays
Operator
Ladies and gentlemen, welcome to the Dexcom Fourth Quarter and Fiscal Year 2023 Earnings Conference Call. My name is Abby and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and a-answer session.
[Operator instructions] As a reminder, the conference is being recorded. I will now turn the call over to Sean Christensen, Vice President of Finance and Investor Relations. You may begin.
Sean Christensen
Thank you, Aby, and welcome to Dexcom's fourth quarter and fiscal year 2023 earnings call. Our agenda begins with Kevin Sayer, Dexcom's Chairman, President, and CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jereme Sylvain, our Chief Financial Officer. Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question so we can provide an opportunity for everyone participating today.
Please note that there are also slides available related to our fourth quarter and fiscal year 2023 performance on the Dexcom investor relations website on the Events and Presentations page. With that, let's review our safe harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance.
All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to Dexcom, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in Dexcom's annual report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP and cash-based results.